A Phase 3 interventional study of pemetrexed and docetaxel in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 51st largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2006, is one of 44 in phase 3, and was the 45th registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 38th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 25 in phase 3, and was the 44th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
Drug: docetaxel
500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
Also known as: LY231514, Alimta
75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
Overall Survival
Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.
Time frame: baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)
Overall Tumor Response
Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.
Time frame: baseline to measured tumor response (up to 24 months after study enrollment)
Progression-Free Survival (PFS)
Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.
Time frame: baseline to measured progressive disease (up to 24 months after study enrollment)
Duration of Response
Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as "Number of Patients with Disease Progression".
Time frame: time of response to progressive disease (up to 24 months)
Pharmacology Toxicity
Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.
Time frame: first dose of study drug up to 24 months
| Milestone | Pemetrexed | Docetaxel |
|---|---|---|
| Started | 107 | 104 |
| Received at least one dose of study drug | 106 | 102 |
| Completed | 46 | 47 |
| Not completed | 61 | 57 |
| Withdrew: Death due to study disease | 55 | 45 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Death due to adverse event | 1 | 3 |
| Withdrew: Death due to indeterminate cause | 1 | 0 |
| Withdrew: Death not study related | 0 | 1 |
Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.
| participants | Pemetrexed | Docetaxel |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 10 | 4 |
| Stable Disease | 33 | 46 |
| Progressive Disease | 49 | 36 |
| Early Death from Malignant Disease | 7 | 6 |
| Early Death from Other Causes | 1 | 1 |
| Unknown | 4 | 5 |
Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.
| months | Pemetrexed | Docetaxel |
|---|---|---|
| Progression-Free Survival (PFS) | 2.8 (1.8 to 3.1) | 3.1 (2.8 to 3.7) |
Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as "Number of Patients with Disease Progression".
No measurements were reported for this outcome.
Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.
| participants | Pemetrexed | Docetaxel |
|---|---|---|
| Serum Glutamic Pyruvic Transaminase | 1 | 0 |
| Hemoglobin | 7 | 3 |
| Leukocytes | 4 | 21 |
| Lymphopenia | 1 | 0 |
| Neutrophils/Granulocytes | 5 | 29 |
| Platelets | 7 | 0 |
| Hypokalemia | 0 | 1 |
| Anorexia | 1 | 0 |
| Constipation | 0 | 1 |
| Diarrhea | 0 | 5 |
| Enteritis | 0 | 1 |
| Fatigue (Asthenia, Lethargy, Malaise) | 3 | 5 |
| Febrile Neutropenia | 2 | 4 |
| Infection (Clinical/Microbiological: Neutrophils) | 0 | 1 |
| Infection (Unknown: Pneumonia) | 0 | 1 |
| Mucositis/Stomatitis | 1 | 0 |
| Neuropathy: Motor | 0 | 1 |
| Pain: Thorax Not Otherwise Specified (NOS) | 0 | 1 |
| Pericardial Effusion (Non-Malignant) | 1 | 0 |
| Pulmonary/Upper Respiratory - Other | 1 | 0 |
| Rash/Desquamation | 1 | 0 |
Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.
| months | Pemetrexed | Docetaxel |
|---|---|---|
| Overall Survival (up to 24 months) | 11.7 (8.7 to NA) | 12.2 (9.1 to NA) |
| Overall Survival (up to 30 months) | 11.4 (8.6 to 13.4) | 11.5 (8.9 to 15.2) |
Number of patients who have died or have had progression of disease. This outcome substitutes for the outcome on Duration of Response.
| participants | Pemetrexed | Docetaxel |
|---|---|---|
| Number of Patients With Disease Progression | 4 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 10/106 (9.4%) | 99/106 (93.4%) |
| Docetaxel | — | 12/102 (11.8%) | 95/102 (93.1%) |
| Event | Pemetrexed | Docetaxel |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/106 | 1/102 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/106 | 0/102 |
| Pericardial effusionCardiac disorders | 2/106 | 0/102 |
| PyrexiaGeneral disorders | 2/106 | 0/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/106 | 1/102 |
| AnaemiaBlood and lymphatic system disorders | 0/106 | 1/102 |
| NeutropeniaBlood and lymphatic system disorders | 0/106 | 1/102 |
| DiarrhoeaGastrointestinal disorders | 0/106 | 1/102 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/106 | 1/102 |
| FatigueGeneral disorders | 1/106 | 1/102 |
| Event | Pemetrexed | Docetaxel |
|---|---|---|
| FatigueGeneral disorders | 48/106 | 42/102 |
| AnorexiaMetabolism and nutrition disorders | 38/106 | 30/102 |
| Alanine aminotransferase increasedInvestigations | 33/106 | 10/102 |
| White blood cell count decreasedInvestigations | 15/106 | 31/102 |
| Neutrophil count decreasedInvestigations | 13/106 | 30/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 31/106 | 22/102 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/106 | 24/102 |
| Aspartate aminotransferase increasedInvestigations | 23/106 | 6/102 |
| NauseaGastrointestinal disorders | 21/106 | 12/102 |
| RashSkin and subcutaneous tissue disorders | 21/106 | 4/102 |
| Age Continuous(years) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| Mean | 56.4 ± 9.33 | 55.9 ± 11.41 | 56.1 ± 10.39 |
| Sex: Female, Male(Participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| Female | 34 | 43 | 77 |
| Male | 73 | 61 | 134 |
| Race/Ethnicity, Customized(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| East Asian | 107 | 104 | 211 |
| Region of Enrollment(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| China | 107 | 104 | 211 |
| Basis for Pathological Diagnosis(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| Cytological | 34 | 35 | 69 |
| Histopathological | 73 | 69 | 142 |
| Disease Stage(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| Stage IIIA | 2 | 2 | 4 |
| Stage IIIB | 24 | 18 | 42 |
| Stage IV | 81 | 84 | 165 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| 0 - Fully Active | 11 | 16 | 27 |
| 1 - Ambulatory, Restricted Strenuous Activity | 84 | 77 | 161 |
| 2 - Ambulatory, No Work Activities | 12 | 11 | 23 |
| Number of Sites of Metastatic Disease(participants) | Pemetrexed | Docetaxel | Total |
|---|---|---|---|
| 1 Site | 10 | 15 | 25 |
| 2 Sites | 32 | 31 | 63 |
| 3 Sites | 34 | 30 | 64 |
| 4 Sites | 11 | 12 | 23 |
| 5 Sites | 11 | 8 | 19 |
| 6 Sites | 4 | 8 | 12 |
| 7 Sites | 3 | 0 | 3 |
| 8 Sites | 1 | 0 | 1 |
| 9 Sites | 0 | 0 | 0 |
| 10 Sites | 1 | 0 | 1 |
2 further baseline measures are reported on the registry.
The record gives a start of Oct 2006, a primary completion of Dec 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →